Breaking

Anthropic Fights Trump Administration Over AI Model Export Controls Respond.io raises $62.5M Series B to scale customer conversation management platform Vozinha, 40, Shines in World Cup Debut with Stellar Goalkeeping Performance Oklahoma Primaries Test Trump's Influence in Key Races Edwards Air Force Base: A History of Innovation and Tragedy Iranian Americans Protest, Divide Over Team at World Cup Match UFC CEO Dana White Says White House Event Was a One-Off G7 Leaders Tackle Ukraine War, Middle East Crisis at Summit DC Voters Head to Polls for Mayor, Congressional Delegate Primaries Election Conspiracy Theorist Wins Nevada GOP Secretary of State Primary Anthropic Fights Trump Administration Over AI Model Export Controls Respond.io raises $62.5M Series B to scale customer conversation management platform Vozinha, 40, Shines in World Cup Debut with Stellar Goalkeeping Performance Oklahoma Primaries Test Trump's Influence in Key Races Edwards Air Force Base: A History of Innovation and Tragedy Iranian Americans Protest, Divide Over Team at World Cup Match UFC CEO Dana White Says White House Event Was a One-Off G7 Leaders Tackle Ukraine War, Middle East Crisis at Summit DC Voters Head to Polls for Mayor, Congressional Delegate Primaries Election Conspiracy Theorist Wins Nevada GOP Secretary of State Primary

Zepbound

Steady2 stories2 sourcesLast updated: 5/28/2026

Related TopicsCVS Health Eli Lilly Novo Nordisk Foundayo Wegovy Weight Loss Drugs Pharmacy Benefit Management glp-1 drugs

Latest Stories

CVS Health to Restore Coverage of Eli Lilly's Weight Loss Drugs

5/28/2026AI summary

CVS Health to Restore Coverage of Eli Lilly's Weight Loss Drugs

CVS Health will restore coverage of Eli Lilly's weight loss injection Zepbound on Oct. 1 and add coverage of its new obesity pill Foundayo on June 1, making both GLP-1 medications co-preferred options on its standard commercial formulary, affecting 25-30 million Americans and boosting Lilly's market position against Novo Nordisk.

CNBC US Markets

Millions Lose Insurance Coverage for GLP-1 Weight Loss Drugs as Patients Face Rising Costs

Health·4/22/2026AI summary

Millions Lose Insurance Coverage for GLP-1 Weight Loss Drugs as Patients Face Rising Costs

Research shows 12 million people lost coverage for Zepbound and 12 million for Wegovy from 2025 to 2026, with 88% of those who still have coverage facing restrictions. Patients like Meghan Lena, a Massachusetts teacher, describe losing coverage twice within months and being forced to pay $300 monthly for compounded alternatives or face treatment interruption.